Discovery spurred by unique twist of fate

February 21, 2013 by Shawn Hutchins
Discovery spurred by unique twist of fate
Varying images of calcific nodules stained in dark red with surrounding valvular interstitial cells in gray. Images B and D received the highest treatment of gentamicin.

(Medical Xpress)—As people age, or as a result of poor nutrition, heart valves can become damaged by the accumulation of calcium deposits within the tissue. This calcification causes a thickening and hardening of the tissue to the point that it limits normal blood flow.

Bioengineering researchers in Rice Associate Professor Jane Grande-Allen's laboratory analyze the biomechanics of heart-valve tissue and the underlying cellular and of valve disease. One ongoing investigation pursued by her group looks into the roles cellular and matrix components play in normal valve biology and the that can cause the formation of calcified nodules in aortic valve leaflets.

"Very little is known about the intracellular dynamics among genes, proteins and the that guide either normal processes or give rise to abnormalities," Grande-Allen said. "Accumulative efforts in our lab involve investigations into valve- and disease from a more mechanical perspective. Specifically, we look for cues as to how alterations to cells and cellular environments are driven by of the over many years."

In a unique twist of fate, Grande-Allen, graduate student Dena Wiltz and undergraduate student Aditya Kumar found that gentamicin, an aminoglycosidic antibiotic used to treat many types of bacterial infections, significantly reduced the number and size of calcific nodules formed by valvular interstitial cells.

The research, which was detailed in the journal Cardiovascular Engineering and Technology, was initially spurred by the lab's examination of various antibiotics for the occasional prevention of bacterial infections in cell cultures.

"Contamination of is a consistent issue for researchers, said Wiltz, a sixth-year graduate student in the Grande-Allen lab at Rice's BioScience Research Collaborative. Wiltz's research in valve disease is supported by a grant from Baylor College of Medicine.

"Impurities not only adversely affect results, but vast amounts of time and money can be spent managing bacterial contaminates," Wiltz said. "Gentamicin is widely used for the in vitro prevention of cell- and tissue-culture contamination, but it has been reported to affect calcium levels in various cell types. So we decided to add it to our cultures—not to prevent contamination so much as to see if it regulated calcium mineralization by valve cells."

Their investigations paid off. "Not only did we find that dose-dependent increases of gentamicin caused alterations to cellular mineralization, but the findings, along with a literary investigation, spurred insight into the roles cellular components, such as lipids and mitochondria, might play in the development of pathological calcification," Kumar said. He is a senior and co-author on the research paper and has been a member of the Grande-Allen group since the summer of his freshman year.

Aortic valve tissue is made of trilayered connective tissues, and Grande-Allen and her students apply engineering analysis to decode how individual parts of this complex cooperate, respond to cellular signals and are influenced by overall valvular function, growth and the evolution of abnormalities.

"Through a bottom-up approach, we are looking at how valvular interstitial cells—the primary cells within these tissue layers—interact both biologically and mechanically with their surrounding environments," Grande-Allen said. "Although gentamicin has limited clinical use, due to its toxic side effects, our results might prove to be useful in connecting these processes and ultimately in the development of promising pharmaceuticals that curb the progression of heart-valve disease."

Explore further: New scanning strategy could help develop heart disease treatments

More information:

Related Stories

Approval expanded for sapien artificial heart valve

October 22, 2012

(HealthDay)—U.S. Food and Drug Administration approval for the Sapien Transcatheter Heart Valve has been expanded to include additional people with aortic valve stenosis, the medical term for a narrowing of the aortic valve ...

Magnetically levitated tissues could speed toxicity tests

January 24, 2013

In a development that could lead to faster and more effective toxicity tests for airborne chemicals, scientists from Rice University and the Rice spinoff company Nano3D Biosciences have used magnetic levitation to grow some ...

Genetic variation doubles risk of aortic valve calcification

February 6, 2013

Researchers have found a genetic variant that doubles the likelihood that people will have calcium deposits on their aortic valve. Such calcification, if it becomes severe, can cause narrowing or a blockage of the aortic ...

Recommended for you

What powers the pumping heart?

September 25, 2015

Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps—a phenomenon known as contractility.

Sticky gel helps stem cells heal rat hearts

September 24, 2015

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.